SALL2 and ovarian carcinoma: Clinical evidence showed loss of heterozygosity (LOH) at the SALL2 locus in 30% of ovarian cancer patients (Bandera et al., 1997), and recent studies demonstrated that the P2 promoter of SALL2 is susceptible to silencing by methylation (Sung et al., 2013).